• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Erasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    1/20/26 4:05:37 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ERAS alert in real time by email
    8-K
    false 0001761918 0001761918 2026-01-20 2026-01-20
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 20, 2026

     

     

    Erasca, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-40602   83-1217027
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    3115 Merryfield Row

    Suite 300

     
    San Diego, California   92121
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (858) 465-6511

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share   ERAS   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02 Results of Operations and Financial Condition.

    Erasca, Inc. (the “Company”) is providing the following financial information. As of December 31, 2025, our cash, cash equivalents and marketable securities were approximately $341.8 million.

    The cash, cash equivalents and marketable securities information above is based on preliminary unaudited information and management estimates for the year ended December 31, 2025, is not a comprehensive statement of our financial results as of and for the fiscal year ended December 31, 2025, and is subject to completion of our financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this preliminary estimate.

    Pursuant to the rules and regulations of the SEC, the information provided in this Item 2.02 of this Form 8-K shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless otherwise expressly set forth by specific reference in such a filing.

    Forward-Looking Statements

    The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company’s current beliefs and expectations and include, but are not limited to: statements regarding the preliminary estimate of the Company’s cash, cash equivalents and marketable securities as of December 31, 2025. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including, without limitation: our actual results for the fourth quarter or full year of 2025 may differ materially from our preliminary estimates as a result of changes to assumptions and estimates, the completion of review of internal controls over financial reporting or other quarter-end and year-end procedures; and other risks described in the Company’s prior filings with the SEC, including under the heading “Risk Factors” in its annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          Erasca, Inc.
    Date: January 20, 2026     By:  

    /s/ Ebun Garner

          Ebun Garner, General Counsel
    Get the next $ERAS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ERAS

    DatePrice TargetRatingAnalyst
    1/27/2026$16.00Outperform
    Mizuho
    1/7/2026$5.00Overweight
    Piper Sandler
    10/16/2025$4.00Buy
    Stifel
    9/3/2025Buy → Underperform
    BofA Securities
    8/18/2025$2.00Overweight → Equal-Weight
    Morgan Stanley
    3/26/2025$5.00Outperform
    Raymond James
    11/18/2024$6.00Buy
    Jefferies
    3/11/2024$8.00Overweight
    CapitalOne
    More analyst ratings

    $ERAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho resumed coverage on Erasca with a new price target

    Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

    1/27/26 8:45:40 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Erasca with a new price target

    Piper Sandler initiated coverage of Erasca with a rating of Overweight and set a new price target of $5.00

    1/7/26 9:10:17 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Erasca with a new price target

    Stifel initiated coverage of Erasca with a rating of Buy and set a new price target of $4.00

    10/16/25 8:25:25 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $10.00 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other off

    1/23/26 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Announces Pricing of Upsized Public Offering of Common Stock

    SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $225.0 million.

    1/21/26 8:54:39 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Announces Proposed Public Offering of $150 Million of Common Stock

    SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Erasca. In addition, Erasca intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock. There can be no assurance a

    1/20/26 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ERAS
    SEC Filings

    View All

    $ERAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel & Corp. Sec. Garner Ebun was granted 3,902 shares, exercised 120,000 shares at a strike of $1.70 and sold $670,812 worth of shares (120,000 units at $5.59), increasing direct ownership by 18% to 25,076 units (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    1/8/26 9:20:34 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Multani Pratik S

    4 - Erasca, Inc. (0001761918) (Issuer)

    1/5/26 9:00:06 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Liu Jean I

    4 - Erasca, Inc. (0001761918) (Issuer)

    1/5/26 9:00:08 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Erasca Inc.

    8-K - Erasca, Inc. (0001761918) (Filer)

    1/22/26 5:12:27 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Erasca Inc.

    424B5 - Erasca, Inc. (0001761918) (Filer)

    1/22/26 5:10:06 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Erasca, Inc. (0001761918) (Filer)

    1/20/26 4:05:37 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Casdin Alexander W. bought $181,920 worth of shares (80,000 units at $2.27) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    5/22/24 6:57:45 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Start Valerie Denise Harding bought $18,480 worth of shares (10,000 units at $1.85) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/8/23 9:10:12 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lim Jonathan E bought $1,696,179 worth of shares (1,000,000 units at $1.70) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/6/23 7:41:47 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Leadership Updates

    Live Leadership Updates

    View All

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Erasca Appoints Jean Liu to its Board of Directors

    SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

    4/27/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Strengthens Leadership Team with Two Key Executive Appointments

    Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

    1/18/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Financials

    Live finance-specific insights

    View All

    Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

    Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

    5/16/24 8:02:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Reports First Quarter 2024 Business Updates and Financial Results

    Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March

    5/8/24 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

    Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm

    3/27/24 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 5:13:04 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 4:04:32 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Erasca Inc.

    SC 13G - Erasca, Inc. (0001761918) (Subject)

    11/14/24 1:28:34 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care